SCHEMBL23675432

SCHEMBL23675432

O=C(Nc1ccc(NC2CCCC2)cc1Cl)c1cc(Cl)ccc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.55
MEN1 O00255 1/20 0.55
AURKA O14965 1/20 0.55
NPC1 O15118 1/20 0.55
PDPK1 O15530 1/20 0.55
JAK2 O60674 1/20 0.55
GMNN O75496 1/20 0.55
ALDH1A1 P00352 1/20 0.55
EGFR P00533 1/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
CYP1A2 P05177 1/20 0.55
LYN P07948 1/20 0.55
CHRM2 P08172 1/20 0.55
CYP3A4 P08684 1/20 0.55
ADRA2A P08913 1/20 0.55
CYP2D6 P10635 1/20 0.55
MAPT P10636 1/20 0.55
KIT P10721 1/20 0.55
FGFR1 P11362 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26095655 0.99 RAB9A (0.54) RAB9AMEN1AURKANPC1PDPK1
SCHEMBL23675431 0.91 P2RX1 (0.58) RAB9AMEN1AURKANPC1PDPK1
Hydrochloric Acid SCHEMBL23675414 0.89 MEN1 (0.51) RAB9AMEN1AURKANPC1PDPK1
SCHEMBL23675413 0.89 NR1H4 (0.51) RAB9AMEN1AURKANPC1PDPK1
SCHEMBL30100494 0.89 NR1H4 (0.51) RAB9AMEN1AURKANPC1PDPK1
SCHEMBL23675406 0.89 TAS1R3 (0.63) RAB9AMEN1NPC1LMNAMAPT
SCHEMBL30100438 0.88 TMPRSS4 (0.57) MEN1ALDH1A1LMNATP53MAPT
SCHEMBL23685589 0.88 TMPRSS4 (0.57) MEN1ALDH1A1LMNATP53MAPT
SCHEMBL26099029 0.87 MEN1 (0.49) RAB9AMEN1AURKANPC1PDPK1
SCHEMBL23675395 0.87 NPC1 (0.54) RAB9ANPC1ALDH1A1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed
EP-4093401-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING The Board of Regents of the University of Texas System (US) 2022-11-30 EP disclosed
WO-2021151104-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING EIF2AK2, SARS1, ACE RAB9A 4307/4885MEN1 4398/4885AURKA 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.